Acrivon Therapeutics (ACRV) Income from Non-Controlling Interests (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Income from Non-Controlling Interests of -$107000.0 for Q1 2026, up 34.76% year-over-year from -$79402.7 in Q1 2025, and down 10600.0% quarter-over-quarter from -$1000.0 in Q4 2025.
Acrivon Therapeutics (ACRV) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Income from Non-Controlling Interests for 6 consecutive years, with -$107000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 34.76% year-over-year to -$107000.0; the TTM figure through Mar 2026 stood at -$279000.0 (down 179.04% YoY), while the FY2025 annual figure was -$336000.0, down 163.4% from the prior year.
- Income from Non-Controlling Interests eased to -$107000.0 in Q1 2026 per ACRV's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $801000.0 in Q3 2024 and bottomed at -$7.2 million in Q1 2022.
- Historically, Income from Non-Controlling Interests has averaged -$766823.5 across 5 years, with a median of -$1000.0 in 2025.
- Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests soared 540.8% — and 2025, when it slumped 1361.54%.
- Acrivon Therapeutics' Income from Non-Controlling Interests stood at $38000.0 in 2022, then jumped by 476.32% to $219000.0 in 2023, then slumped by 252.97% to -$335000.0 in 2024, then jumped by 99.7% to -$1000.0 in 2025, then slumped by 10600.0% to -$107000.0 in 2026.
- Business Quant data shows ACRV's Income from Non-Controlling Interests at -$107000.0 in Q1 2026, -$1000.0 in Q4 2025, and $6000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37,000.00 |
| Mar 31, 2026 | -107,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | -177,000.00 |
| Mar 31, 2025 | -164,000.00 |
| Dec 31, 2024 | -335,000.00 |
| Sep 30, 2024 | 801,000.00 |
| Jun 30, 2024 | 51,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Dec 31, 2023 | 219,000.00 |
| Sep 30, 2023 | 125,000.00 |
| Jun 30, 2023 | -436,000.00 |
| Mar 31, 2023 | 104,000.00 |
| Dec 31, 2022 | 38,000.00 |
| Sep 30, 2022 | -133,000.00 |
| Jun 30, 2022 | -5.82 Mn |
| Mar 31, 2022 | -7.22 Mn |
| Dec 31, 2021 | -4.34 Mn |
| Sep 30, 2021 | -2.44 Mn |